FMP 010 vaccine

Drug Profile

FMP 010 vaccine

Alternative Names: FMP010/AS01B - GlaxoSmithKline

Latest Information Update: 10 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Walter Reed Army Institute of Research
  • Developer GlaxoSmithKline; Kenya Medical Research Institute; U.S. Army Medical Materiel Development Activity; United States Agency for International Development; Walter Reed Army Institute of Research
  • Class Protein-vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malaria

Most Recent Events

  • 01 Jun 2013 Discontinued - Phase-I for Malaria (Prevention) in Kenya, USA (IM)
  • 01 Jun 2011 No development reported - Phase-I for Malaria (Prevention) in Kenya, USA (IM)
  • 01 Apr 2008 Phase-I clinical trials in Malaria (Prevention) in Kenya, USA (IM) (NCT00666380; NCT02458092)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top